Early toxicity and patient reported quality-of-life in patients receiving proton therapy for localized prostate cancer: a single institutional review of prospectively recorded outcomes

Table 4 Literature review of toxicity data

Study	No. of Patients	Therapy	Median RT Dose Gy or CGE	Median Follow-Up Years	Toxicity Grading Scale	G3+ GU Toxicity	G2+ GU Toxicity	G3+ GI Toxicity	G2+ GI Toxicity
Liauw et al., 2009 [21]	130	IMRT	76	4.4	RTOG	6%^b	37.0%^b	5%^b	14.0%^b
Spratt et al., 2013 [22]	1002	IMRT	86.4	5.5	CTCAE	2.2%	8.5%	0.7%	2.0%
Vora et al., 2013 [23]	302	IMRT	75.6	7.6	CTCAE	2.6%	24.4%	1%	10.9%
Fang et al., 2015 [24]	94	IMRT	79.2	3.9	CTCAE	0%	18.3%	2.1%	10.8%
Fang et al., 2015 [24]	94	PS PBT	79.2	2.4	CTCAE	2.1%	12.8%	0%	12.8%
Slater et al., 2004 [17]	1255	PS PBT	74	5.3	RTOG	1.0%^a	–	1.0%^a	–
Pugh et al., 2013 [15]	291	PS > PBS PBT	76	2.0	RTOG	0%^c	13.4%^c	0.3%^c	9.6%^c
Mendenhall et al., 2014 [13]	211	PS PBT	78–82	5.2	CTCAE	1.0%^a	–	0.5%^a	–
Bryant et al., 2016 [9]	1215	PS PBT	78	5.5	CTCAE	2.9%^a	–	0.6%^a	–
Present study, 2017	192	PBS > PS PBT	79.2	1.7	CTCAE	1.0%	26.4%^c	0.5%	21.3%^c

Abbreviations: PS passive scatter, PBS pencil beam scanning, PBT proton beam therapy, IMRT intensity-modulated radiation therapy, RTOG radiation therapy oncology group, CTCAE common terminology criteria for adverse events, version 4.0
^a = 5-year actuarial rate, ^b = 4-year actuarial rate, ^c = 2-year actuarial rate. No symbol next to a toxicity rate % indicates a rate reported as the number of toxicity events observed over the total number of patients, with varying median follow-up across studies

ISSN: 1748-717X